financetom
Business
financetom
/
Business
/
OptimizeRx Stock Rallies 22% After-Hours Thanks To Q2 Earnings Push
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
OptimizeRx Stock Rallies 22% After-Hours Thanks To Q2 Earnings Push
Aug 7, 2025 8:50 PM

Following the release of its second-quarter financial results, OptimizerRx Corp stock witnessed a 22.66% surge during after-hours trading on Thursday.

Check out the current price of OPRX stock here. 

What Happened: The Michigan-based digital health company’s stock soared to $15.75 per share in extended trading. This increase came after the company’s shares closed at $12.84, which was up 2.88% earlier in the regular session, according to Benzinga Pro data.

OptimizerRx’s second-quarter earnings outperformed market expectations, with a $0.22 beat and revenue of $29.2 million surpassing estimates of $22.6 million.

See Also: Brazil’s President Says ‘Won’t Humiliate Myself’ By Calling Trump — Seeks Joint BRICS Response With China, India To Counter Tariffs

"Our year-to-date results continue to deliver profitable growth ahead of expectations. Contracted revenue is now up more than 30% year-over-year, positioning us for a strong finish to the second half," stated Stephen L. Silvestro, CEO of OptimizeRx ( OPRX ). 

The healthcare communication company has traded between $3.78 and $15.71 over the past 52 weeks. With a market capitalization of $237.48 million, OptimizeRx ( OPRX ) has a trading volume of 419,818 shares, above its average volume of 296,769.

Why It Matters: OptimizeRx’s second-quarter financial results have been impressive, with a 55% year-over-year increase in revenue to $29.2 million. Gross profit also saw a 59% year-over-year rise to $18.6 million. The company’s Generally Accepted Accounting Principles net income for the second quarter was $1.5 million, a significant improvement from the GAAP net loss of $4.0 million in the same period last year, as reported by OptimizerRx.

Following this strong performance, OptimizerRx has raised its full-year 2025 guidance, now expecting a revenue range between $104 million and $108 million and an adjusted earnings before interest, taxes, depreciation, and amortisation (EBITDA) range between $14.5 million and $17.5 million.

As a result, the company’s shares are trading higher, reflecting investor confidence in its growth trajectory and financial performance.

With a strong Momentum in the 94th percentile, Benzinga’s Edge Stock Rankings indicate that OPRX is experiencing short-term consolidation along with medium and long-term upward movement. Know how its momentum lines up with other well-known names.

Read Next:

Trump May End Up Exposing US Consumers As ‘Paper Tigers,’ Says Economist Peter Schiff On 50% India Tariffs

Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Intuit to Cut 10% of Workforce, Close Two Locations
Intuit to Cut 10% of Workforce, Close Two Locations
Jul 10, 2024
12:42 PM EDT, 07/10/2024 (MT Newswires) -- Intuit (INTU) announced plans to layoff 1,800 employees and close two locations as part of a restructuring plan that will enable the financial technology company to increase its investments in artificial intelligence. The move, which will see Intuit shed 10% of its workforce, is expected to cost $250 million to $260 million, according...
US FDA flags shortage of Becton Dickinson's blood test tubes
US FDA flags shortage of Becton Dickinson's blood test tubes
Jul 10, 2024
July 10 (Reuters) - The U.S. Food and Drug Administration issued an alert on Wednesday to laboratories and healthcare providers of a shortage of Becton Dickinson ( BDX )' blood test tubes used in diagnosing bacterial and fungal infections. The regulator urged providers to prioritize patients at the highest risk such as those displaying signs of bloodstream infections, which can...
UBS Previews Canadian Rails' Q2
UBS Previews Canadian Rails' Q2
Jul 10, 2024
12:53 PM EDT, 07/10/2024 (MT Newswires) -- UBS is raising its second quarter estimates for CP Rail to $1.02, which is 2% above consensus but trimming carload estimate for the railway company from -1.4% y/y to -3.4%. Revenue ton miles (RTMs) trended in line with UBS expectations at +6%. The wider spread between carloads and RTMs supports an increase in...
Market Chatter: Apple Looking to Ship 10% More New iPhones in 2024
Market Chatter: Apple Looking to Ship 10% More New iPhones in 2024
Jul 10, 2024
12:31 PM EDT, 07/10/2024 (MT Newswires) -- Apple ( AAPL ) is looking to ship at least 90 million iPhone 16s in the second half of the year, driven by demand for the AI services from its new lineup, Bloomberg reported Wednesday. The company told partners and suppliers that it's aiming for about 10% growth in shipments of new iPhones...
Copyright 2023-2026 - www.financetom.com All Rights Reserved